Featured Articles

Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III POLO trial. Results from…
Read More...

AbbVie and Voyager Therapeutics announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological…
Read More...

Abbott and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital…
Read More...

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT for the treatment of adults and children with…
Read More...

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary…
Read More...

Merck, known as MSD outside the United States and Canada, announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck’s…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This…
Read More...

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting…
Read More...

The Epilepsy Society and UCB, a global biopharmaceutical company headquartered in Belgium, with a significant UK R&D hub in Slough, UK, have announced an exciting new collaboration…
Read More...

GlaxoSmithKline plc and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa).…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB…
Read More...

The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of…
Read More...

The SCHOTT technology group is set to invest around 300 million euros in the next three years in the expansion of its core business of glass tubing as the starting material for…
Read More...

Phoenix Molecular Designs announced that it has entered into a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer (TNBC). The Roche CDx identifies…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen…
Read More...

Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma…
Read More...

X-Chem, Inc., a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced a drug discovery…
Read More...